Myogenic Progenitor Isolation Using CD54 Surface Markers

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for isolating myogenic progenitor cells from pluripotent stem cells are heterogeneous and often involve genetically manipulated markers like GFP, which can induce immune responses, hindering clinical translation and quality control.

Innovation Solution

The use of CD54, Alpha9 integrin (α9β1), and Syndecan2 (SDC2) as surface markers allows for the isolation of myogenic progenitor cells through Fluorescent Activated Cell Sorting (FACS) or magnetic sorting, avoiding genetically manipulated markers and ensuring purity and clinical compatibility.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If genetically manipulated markers like GFP are used to isolate myogenic progenitor cells, then isolation can be achieved, but immune responses are induced and clinical translation is hindered

Engineering Contradiction:

Improveisolation capabilityVSAvoidimmune response

Core Design Contradiction:

Ease of manufactureVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and eliminates the genetically manipulated markers (GFP) from the isolation process, replacing them with endogenous surface markers (CD54, Alpha9 integrin, Syndecan2) that are naturally expressed on myogenic progenitor cells. This removal of harmful genetic modifications resolves the immune response issue while maintaining isolation capability through alternative marker-based sorting methods.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the isolation parameters from using exogenous genetic markers to using endogenous surface protein markers. By switching to markers that are naturally present on the cell surface (CD54, Alpha9 integrin, Syndecan2), the method achieves both clinical compatibility and effective isolation without requiring genetic manipulation.

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If heterogeneous isolation methods are used, then various cell types can be obtained, but purity and homogeneity of myogenic progenitor cells are reduced

Engineering Contradiction:

Improveisolation flexibilityVSAvoidcell purity

Core Design Contradiction:

Adaptability or versatilityVSManufacturing precision

Solution Approach 1:

The patent segments the isolation process into a multi-marker sorting strategy using CD54, Alpha9 integrin, and Syndecan2. By combining multiple specific markers rather than using a single heterogeneous method, the patent achieves both versatility in isolation approach and high purity in the resulting myogenic progenitor cell population.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent employs multiple surface markers (CD54, Alpha9 integrin, Syndecan2) that can be used individually or in combination, providing a universal and flexible isolation system. This multi-functional approach allows for high purity isolation while maintaining adaptability in the isolation methodology.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method provides a homogeneous population of myogenic progenitor cells that contribute to long-term muscle regeneration in vivo, overcoming the limitations of existing protocols by ensuring purity and clinical compatibility.

Implementation Method 1

The myogenic progenitor cells are isolated by Fluorescent Activated Cell Sorting (FACS)

Methodology Applied

Scientific EffectFluorescence: Fluorescence

Implementation Method 2

The myogenic progenitor cells are isolated by Fluorescent Activated Cell Sorting (FACS) or magnetic sorting

Methodology Applied

Scientific EffectFluorescent Activated Cell Sorting:

Implementation Method 3

The myogenic progenitor cells are isolated by Fluorescent Activated Cell Sorting (FACS) or magnetic sorting

Methodology Applied

Scientific EffectMagnetism: Magnetism

Data Source

PatentUS12529033B2Method of isolating myogenic progenitors using CD54

Publication Date: 2026.01.20 REGENTS OF THE UNIVERSITY OF MINNESOTA

AI summary

Provided herein are isolated myogenic progenitor cells, methods to isolate myogenic progenitor cells and method of their use.